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Background. Diabetic kidney disease (DKD) is one of the severest complications of diabetes. Microalbumi-
nuria (MAU) is one of the first signals of DKD and an important pathogenetic mechanism of disease progression. 
With diabetes antioxidant properties worsen significantly.
Objective. The aim was to investigate the effect of L-arginine on oxidative stress parameters and microal-
buminuria in type 2 diabetes mellitus and chronic kidney disease patients.
Methods. In total, 57 patients with type 2 diabetes mellitus and chronic kidney disease and 30 healthy in-
dividuals (control group) took part in the study. The patients were divided into 2 congruent groups. The 1-st group 
of patients (n=33), in addition to standard therapy, received L-arginine 4.2 g intravenously for 5 days, after that 
they took it 1.0 g orally three times a day during meals for 1 month. The second group of patients (n=24) received 
a standard therapy.
The concentration of lipid peroxidation products was measured by a spectrophotometric method. The de-
termination of MAU was carried out in morning portion of urine immunological semiquantitative using test strips.
Results. Significant improvement in indexes of lipid peroxidation was observed in both groups after thera-
py (p˂0.01), but in patients treated with L-arginine it was more expressed (p˂0.01). The standard therapy did not 
significantly affect the level of MAU (p˃0.05). The patients treated with L-Arginine, showed a significant reduction 
in MAU (p˂0.01).
Conclusions. L-arginine facilitates the correction of lipid peroxidation processes and reduces the severity 
of microalbuminuria in patients with diabetic kidney disease that slows down its progression.
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Introduction
 In recent decades a number of patients 
with diabetes mellitus (DM) is increased, the 
patients with type 2 diabetes mellitus are a 
significant share of them [1, 2, 3]. 
Diabetic kidney disease (DKD) is one of the 
severest complications of diabetes; it is regis-
tered in 20–30% of patients with diabetes. 
Among the patients, who receive renal replace-
ment therapy, the share of people with DKD is 
about 40–50% [2, 4]. It is established that 10-
20% of patients with diabetes die from chronic 
renal failure [4, 5].
Microalbuminuria (MaU) is one of the first 
signals of DKD. It is not only the symptoms but 
also an important pathogenetic mechanism of 
progression [6, 7]. According to recent studies, 
MAU is considered to be an independent predic-
tor of progressive renal disease [6, 7]. Despite 
the fact that MAU is regarded as a risk factor, 
in the timely diagnosis and adequate treatment 
it can achieve the level of recourse normoalbu-
minuric [6, 8]. But in 30–45% of patients over 
10 years old the disease progresses to pro-
teinuria. On the other hand, in 20% of patients 
over 20 years old a terminal kidney failure is 
developing either [6, 7].
With diabetes antioxidant properties wors-
en significantly. the activity of antioxidant de-
fence in the tissues is reduced; a lipid peroxida-
tion is disordered that has repeatedly been 
proven in experimental diabetes [9, 10]. It is 
important to reveal as soon as possible the 
disorders of pro- and antioxidant system for 
diagnosis and monitoring of the health state. 
The timely correction of changes can prevent 
the progression of vascular complications of 
diabetes [9].
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The aim of our research was to investigate 
the effect of L-arginine on oxidative stress pa-
rameters and microalbuminuria in type 2 dia-
betes mellitus and chronic kidney disease pa-
tients.
Methods 
A total of 57 patients with type 2 diabetes 
mellitus and I-V stages of chronic kidney dis-
ease took part in the study. There were 27 (47%) 
men and 30 (53%) women among them. The 
average age of the patients was (58.7±1.2) years 
old. The average duration of diabetes is 
(11.4±0.9) years. The average illness period of 
CKD is (2.5±0.3) years. The average weight of 
patients was (81.7±1.4) kg. 30 healthy individu-
als composed the control group.
The diagnosis was established by the Sec-
ond National Congress which was adopted as 
nephrology classification of diseases of the 
urinary system in 2005. The stage of CKD was 
determined by glomerular filtration rate (gfR), 
defined by the formula CKD-EPi [11]. 
The concentration of thiobarbituric acid 
reactive substances (TBARS) was determined in 
the blood serum by a spectrophotometric me-
thod [12]. We also evaluated the concentrations 
of glutathione (SH-group) [13], catalase [14], 
superoxide dismutase (SOD) [15] in the blood 
plasma. 
The determination of MAU was carried out 
in morning portion of urine immunological 
semiquantitative using test strips CLINITEK® 
Microalbumin 2 Strips (Germany) by means of 
the unit CLINITEK Status® + Analyser (Germa-
ny). MAU was diagnosed at the level of urinary 
albumin excretion within 30–300 mg/day, nor-
moalbuminuria – less than 30 mg/day.
The patients with DKD were divided into 2 
congruent groups: the 1-st group of patients 
(n=33), who, in addition to standard therapy 
received L-arginine 4.2 g intravenously for 5 
days, after that they took it 1.0 g orally three 
times a day during meals for 1 month. The 
second group of patients (n=24) received a 
standard therapy. The results were compared 
with those of the healthy controls (n 30).
The data were subjected to statistical re-
search processing. For this purpose the applica-
tion package Statistica (StartSoft USA, v.12) was 
used: the method of parametric and nonpara-
metric statistics, Spearman rank correlation to 
determine the connection between the studied 
parameters. Statistically significant differences 
in p˂0.05 are considered.
Results 
Analyzing the results, it was found outthat 
100% of patients with DKD have lipid peroxi-
dation disorders (Fig. 1).
The average level of MAU in the DKD pa-
tients before treatment is in 25.6 times higher 
than in the control group (Fig. 2).
We have analysed the findings of MAU, 
depending on the method of treatment in DKD 
patients groups before and after treatment 
(Table 2).
Discussion 
The average levels of TBARS and SH-groups 
in the patients with DKD before treatment were 
significantly increased compared with the cor-
responding values in the control group (p˂0.01). 
Significantly reduced SOD and catalase activity 
were detected in the observed DKD patients 
before treatment compared with the control 
group (p˂0.01). no significant difference in lipid 
peroxidation indexes was noted between two 
DKD patients groups before treatment (р˃0.05). 
Significant improvement in lipid peroxidation 
indexes was observed in both DKD patients 
groups after therapy (p˂0.01), but in the pa-
Fig. 1. The level of lipid peroxidation indexes in DKD patients 
before treatment and control groups.
* – The difference between the control group and DKD 
patients group is significant (р˂0.01).
Fig. 2. The level of MAU in the DKD patients before treat-
ment and in the control groups.
* – The difference between the control group and the DKD 
patients group is significant (р˂0.01)
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tients treated with L-arginine it was more ex-
pressed (p˂0.01).
the standard therapy did not significantly 
affect the level of MaU (p˃0.05). a significant 
reduction in MaU (p˂0.01) was proved in the 
patients treated with L-Arginine.
The role of oxidative stress in the pathogen-
esis of diabetes has been examined repeat-
edly in the experimental models. Renal cortical 
superoxide production is increased in the 
early stage of experimental diabetes that leads 
to vasoconstriction of afferent arteriole [16]. 
Recent studies in experimental models of dia-
betic nephropathy indicate that vascular syn-
thesis of NO protects from progression of renal 
lesions in diabetes [17]. L-arginine is a semi-
essential amino acid and also the main source 
for the generation of NO via nitric oxide syn-
thase [18]. 
Recent study demonstrated that L-arginine 
supplementation in type II diabetic rats was 
beneficial by preserving glomerular filtration 
rates, presumably via increased renal endothe-
lial nitric oxide synthase levels, that leads to 
renal vasodilation [19].
In our present research L-arginine supple-
mentation, which stimulates nitric oxide syn-
thesis, causes a pronounced improvement in 
lipid peroxidation indexes and a significant 
re duction in MAU in the patients with DKD.
Conclusions 
In patients with DKD, the decrease in activity 
of SOD and catalase and the increase of TBARS 
The effects of treatment on lipid peroxidation indexes are presented in Table 1.
Table 1. The dynamics of lipid peroxidation indexes in DKD patients before and after treatment 
depending on different treatment regimens, M±m
Indexes
Groups p 
group І 
(n=33)
group ІІ
(n=24) p1 p2 p3 
TBARS,
mkmol/l
Before
treatment
6.26±0.20 6.20±0.13 р˃0.05  
After 
treatment
3.81±0.27 5.27±0.46 р˂0.01 р˂0.01 р˂0.05
SOD,
%
Before
treatment
41.76±0.68 41.45±0.66 р˃0.05   
After 
treatment
55.61±1.42 43.21±1.18 р˂0.01 р˂0.01 р˃0.05 
SH-groups,
mlmol/l
Before
treatment
42.59±1.23 43.71±2.08 р˃0.05   
After 
treatment
57.05±1.98 51.14±1.65 р˂0.05 р˂0.01 р˂0.05 
Catalase,
%
Before
treatment
53.74±2.16 51.46±1.18 р˃0.05   
After 
treatment
31.39±2.80 47.25±2.88 р˂0.01 р˂0.01 р˃0.05 
notes:
1. p1 – significant difference in performance between groups before and after treatment.
2. p2 – significant difference in performance in the first group before and after treatment.
3. p3 – significant difference in performance in the second group before and after treatment.
Table 2. The dynamics of MAU levels, depending on different treatment regimens, M±m
МАU
mg/day
Groups p
group І 
(n=23)
group ІІ
(n=24)
p1 p2 p3 
Before
treatment
180.7±19.9 188.6±15.6 р˃0.05   
After 
treatment
51.4±15.9 149.2±15.5 р˂0.01 р˂0.01 р˃0.05 
notes:
1. p1 – significant difference in performance between groups before and after treatment.
2. p2 – significant difference in performance in the first group before and after treatment.
3. p3 – significant difference in performance in the second group before and after treatment.
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and SH-group parameters is observed that 
proved a lipid peroxidation disorder.
L-arginine in the standard therapy facilitates 
the correction of lipid peroxidation processes 
and reduces the severity of microalbuminuria 
in patients with diabetic kidney disease that 
slows down its progression.
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